Androgen receptor (AR) signaling is critical for the tumorigenesis and development of prostate cancer, as well as the progression to castration-resistant prostate cancer. We previously showed that the heterochromatin protein 1 (HP1) b isoform plays a critical role in transactivation of AR signaling as an AR coactivator that promotes prostate cancer cell proliferation. However, the roles of other HP1 isoforms, HP1a and HP1g, in AR expression and prostate cancer remain unclear. Here, we found that knockdown of HP1g, but not HP1a, reduced AR expression and cell proliferation by inducing cell cycle arrest at G1 phase in LNCaP cells. Conversely, overexpression of full-length HP1a and its C-terminal deletion mutant increased AR expression and cell growth, whereas overexpression of HP1g had no effect. Similarly, HP1a overexpression promoted 22Rv1 cell growth, whereas HP1g knockdown reduced the proliferation of CxR cells, a castration-resistant LNCaP derivative. Taken together, HP1 isoforms distinctly augment AR signaling and cell growth in prostate cancer. Therefore, silencing of HP1b and HP1g may be a promising therapeutic strategy for treatment of prostate cancer.
Introduction
Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer-related death of men in developed countries (Siegel et al. 2012) . Prostate-specific antigen (PSA) screening has improved early detection of prostate cancer and has recently been proved to reduce the risk of death by prostate cancer (Schröder et al. 2009 , Hugosson et al. 2010 , Andriole et al. 2012 . However, a quarter of early-stage prostate cancer patients still suffer from relapse of the disease despite surgical and/or radiation therapy. In addition, many patients with prostate cancer are diagnosed at an advanced stage of the disease. Although most prostate cancers are originally androgen dependent and respond well to androgen-deprivation therapy (ADT), they eventually become castration-resistant prostate cancer (CRPC) during ADT, which is thought to remain dependent on androgen receptor (AR) signaling for growth in a low-androgen milieu (Ryan & Tindall 2011) .
The AR is a member of the class I subgroup of the nuclear receptor superfamily and a ligand-dependent transcription factor. The androgen/AR signaling pathway is thought to play a central role in the development and progression of prostate cancer including CRPC. The mammalian heterochromatin protein 1 (HP1) family plays a critical role in a variety of cellular processes including centromere stability, telomere stability, regulation of gene expression, DNA repair, cellular senescence, and cancer progression through their activities in DNA and its interacting proteins (Zhang & Adams 2007 , Dialynas et al. 2008 , Ayoub et al. 2009 ). Three mammalian HP1 isoforms, HP1a (CBX5), HP1b (CBX1), and HP1g (CBX3), have been identified in humans. Each of these heterochromatins contains two conserved domains, a chromodomain (CD) interacting with dimethylated Lys9 of histone H3 and a chromoshadow domain (CSD) interacting with the PxVxL motif of its partner, which are separated by a flexible hinge region (Kwon & Workman 2011) . HP1 isoforms are known to exhibit different subnuclear localizations in interphasic nuclei. HP1a is mainly centromeric, HP1b is also centromeric, but to a lesser extent, and HP1g is located in both euchromatic and heterochromatic compartments (Dialynas et al. 2007) . HP1 heteromers are associated with nucleosomal core histones (Zhao et al. 2000) and reduce the transcription of nearby promoters when tethered to DNA (Cryderman et al. 1999) . Furthermore, HP1 isoforms in mice and humans interact directly with the transcriptional corepressor TIFb, supporting the hypothesis that HP1 isoforms play a role in gene silencing (Nielsen et al. 1999) . However, it has been recently reported that HP1 isoforms may work at euchromatic regions and as a gene activator despite their name, localization, and suggested function (Piacentini et al. 2003 , Hediger & Gasser 2006 , de Wit et al. 2007 , Fanti & Pimpinelli 2008 . On the other hand, in several cancers, HP1a expression has been reported to be decreased compared with that in the corresponding normal tissues (Pomeroy et al. 2002 , Wasenius et al. 2003 . In addition, reduction of HP1a expression has been observed in various cancers including cancers undergoing progression (Dialynas et al. 2008) . However, several recent reports show that HP1 isoforms are upregulated in various tumor tissues, compared with At 72 h post-transfection, whole cell extracts were subjected to western blotting using the indicated antibodies. (C) LNCaP cells were transfected with 0.5 mg/ml of the AR-Luc #3 reporter plasmids, 20 nM of the indicated siRNA, and 0.05 mg/ml pRL-TK and then incubated for 48 h. Firefly luciferase activity was normalized to the corresponding Renilla luciferase activity. All values represent at least three independent experiments. The luciferase activity in cells transfected with control siRNA was defined as 1. Boxes, mean; bars, GS.D. *P!0.05 (compared with control siRNA). those in normal tissues, and increases according to tumor progression (De Koning et al. 2009 , Takanashi et al. 2009 .
Recently, we reported that HP1b plays a tumorpromoting role in prostate cancer through transactivation of AR signaling as an AR coactivator that promotes prostate cancer cell proliferation (Shiota et al. 2010a) . However, except for HP1b, the functions of the HP1 family in AR signaling and prostate cancer cell proliferation remain unknown. Additionally, the roles of each domain of HP1 in AR signaling and cancer cell proliferation remain unclear. Therefore, the aim of this study was to determine the functions of the HP1 family in association with the AR and prostate cancer cell proliferation.
Materials and methods

Cell culture
LNCaP and 22Rv1 human prostate cancer cells were cultured in RPMI 1640 (Invitrogen) containing 10% fetal bovine serum. Passage 10-40 LNCaP cells were used in experiments. A castration-resistant derivative of LNCaP cells, LNCaP-CxR cells (referred to as CxR cells), was established and maintained as described previously (Shiota et al. 2010b) . The cell lines were maintained at 37 8C with 5% CO 2 .
Antibodies
Antibodies against the AR (sc-815) and green fluorescent protein (GFP) (sc-8334) were purchased from Santa Cruz Biotechnology. Anti-HP1a (#2623) and anti-HP1g (#2619) antibodies were purchased from Cell Signaling Technology (Cambridge, MA, USA). Anti-HP1b (ab49938), anti-PSA, anti-b-actin, and anti-HA antibodies were purchased from Abcam (Cambridge, MA, USA), Epitomics (Burlingame, CA, USA), Sigma, and Roche Applied Science respectively.
Plasmid construction
The AR reporter plasmid (AR-Luc #3) was constructed as described previously (Shiota et al. 2010b ). Construction of pCMV-HA-HP1a, pCMV-HA-HP1b, and pCMV-HA-HP1g plasmids expressing N-terminal HA-tagged HP1a, HP1b, and HP1g proteins respectively has been described previously (Shiota et al. 2010a) . To prepare GFP-HP1a, GFP-HP1b, and GFP-HP1g plasmids expressing N-terminal GFP-tagged HP1a, HP1b, and HP1g proteins, respectively, EcoRI-SalI fragments of HP1a, HP1b, and HP1g cDNAs from pCMV-HA-HP1a, pCMV-HA-HP1b, and pCMV-HA-HP1g were inserted into the EcoRI-SalI sites of pEGFP plasmids (C3; Invitrogen) respectively. The pCMV-HA-HP1b DC (aa 1-116) plasmid expressing the N-terminal HA-tagged C-terminally deleted HP1b protein was created by deletion of the XhoI fragment from the pCMV-HA-HP1b plasmid. Other deletion mutants were constructed from GFP-HP1a, GFP-HP1b, GFP-HP1g, and pCMV-HA-HP1b plasmids using a KOD Mutagenesis Kit (Toyobo, Osaka, Japan) with the following primer pairs: The integrity of mutated plasmids was confirmed by sequencing. To construct pCMV-HA-HP1a DC (aa 1-112), pCMV-HA-HP1a DN (aa 113-190), pCMV-HA-HP1g DC (aa 1-110), and pCMV-HA-HP1g DN (aa 111-182) plasmids, XhoI-SalI fragments from GFP-HP1a DC, GFP-HP1a DN, GFP-HP1g DC, and GFP-HP1g DN were inserted into XhoI-SalI sites of pCMV-HA plasmids respectively.
Western blotting
The preparation of whole cell extracts and western blotting were performed as described previously (Shiota et al. 2010a (Shiota et al. ,b, 2011a .
Knockdown analysis using siRNA
Knockdown analysis using siRNA was performed as described previously (Shiota et al. 2010a (Shiota et al. ,b, 2011a . Briefly, the following double-stranded RNA oligonucleotides were commercially generated: 5 0 -CAU- Luciferase reporter assay, RNA isolation, RT-PCR and quantitative real-time PCR, cell proliferation assay, and flow cytometry
These procedures were performed as described previously (Shiota et al. 2010a (Shiota et al. ,b, 2011a .
Statistical analysis
A t-test was used for statistical analysis. P values !0.05 were considered to be statistically significant.
Results
HP1g knockdown transcriptionally reduces AR expression
First, we functionally analyzed AR expression by knockdown using HP1-specific siRNAs in LNCaP prostate cancer cells. HP1b has been shown to affect PSA expression but not AR expression as an AR coactivator in our previous study (Shiota et al. 2010a) . Similarly, HP1a knockdown exerted no effect on AR expression. On the other hand, HP1g silencing reduced the AR transcript level (Fig. 1A) . Consistently, AR protein expression was also suppressed by HP1g silencing (Fig. 1B) , and also major AR-target gene PSA expression was suppressed by HP1b and HP1g knockdown. In addition, using an AR reporter plasmid (AR-Luc #3) in a luciferase reporter assay, we found reduced luciferase activity by HP1g silencing, indicating that HP1g knockdown downregulates AR transcription (Fig. 1C) . HP1g silencing reduces prostate cancer cell proliferation by inducing cell cycle arrest at G1 phase Next, we investigated the effects of HP1 isoforms on prostate cancer cell proliferation by HP1 knockdown. Previously, we showed that HP1b knockdown reduces prostate cancer proliferation by suppressing AR transactivation (Shiota et al. 2010a) . Here, we examined the effect of HP1a and HP1g on cell proliferation. The data showed that HP1g silencing reduced LNCaP cell proliferation, whereas HP1a knockdown did not affect cell growth ( Fig. 2A) . To reveal the mechanism of cell growth retardation by HP1g silencing, we performed cell cycle analysis using flow cytometry. As shown in Fig. 2B , HP1g suppression resulted in an accumulation of LNCaP cells in G1 phase, indicating cell growth suppression by inducing cell cycle arrest at G1 phase.
Overexpression of HP1 affects AR expression and prostate cancer cell proliferation
Next, we examined the effect of HP1 overexpression on AR expression and prostate cancer cell proliferation. To overexpress the HP1 family, we constructed HA-tagged HP1 expression plasmids, as well as deletion mutants to investigate the roles of the CD and CSD (Fig. 3A) . The expression of HA-tagged full-length and deletion-mutant HP1 isoforms was confirmed by western blotting using whole cell extracts (Fig. 3B) . Next, AR transcript levels were examined after overexpression of various HP1 isoforms. As shown in Fig. 4A , overexpression of HP1a and HP1a DC increased the AR transcript level, which was supported by the results of luciferase reporter assays using an AR reporter plasmid (Fig. 4B ). Furthermore, cell proliferation was enhanced by overexpression of HP1b, which was in agreement with our previous report, as well as full-length HP1a and HP1a DC (Fig. 4C) . Furthermore, we examined the role of the HP1 family in prostate cancer cell proliferation using another AR-expressing prostate cancer cell line, 22Rv1. Expression of GFP-HP1 isoforms in 22Rv1 cells was confirmed by western blotting as shown in Fig. 5A . After overexpression of the HP1 family, 22Rv1 cell proliferation was augmented by HP1b and more strongly by HP1a (Fig. 5B) .
HP1 expression and function in CRPC
To investigate the relevance of the HP1 family in CRPC, we compared the expression of HP1 isoforms between LNCaP cells and its castration-resistant derivative, CxR cells. We found that HP1b expression was elevated in CxR cells, as well HP1b knockdown resulted in decreases of PSA expression and CxR cell proliferation (Shiota et al. 2010a ). In addition, HP1a was upregulated, while HP1g expression was comparable in CxR cells (Fig. 6A) . Next, we examined the effect of HP1 knockdown on AR expression. As shown in Fig. 6B , AR expression was also reduced in CxR cells by HP1g silencing, which was similar to that in LNCaP cells (Fig. 6B) . As a result, HP1g knockdown also suppressed CxR cell proliferation (Fig. 6C) .
Discussion
Classically, the HP1 family has been thought to have suppressive effects on cancer growth and progression. For example, it has been reported that HP1a expression is reduced in invasive human breast cancer cell lines compared with that in non-invasive breast cancer cell lines (Kirschmann et al. 1999) . Overexpression of HP1a in invasive cells reduces their in vitro invasive potential (Kirschmann et al. 2000) , whereas reducing its expression increases their invasive potential (Norwood et al. 2006) . These data suggest that HP1a acts as a progression suppressor in breast cancer cells. In addition, reduction of HP1a expression has been observed in metastatic colon cancer cell lines compared with that in non-metastatic cell lines (Ruginis et al. 2006) , and in papillary thyroid carcinoma compared with that in normal thyroid tissue (Wasenius et al. 2003) , as reviewed by Dialynas et al. (2008) . In line with this finding, HP1 isoforms have been reported to be downregulated in mouse prostate cancer (Shapiro et al. 2008) .
However, recent findings suggest a conceptual shift from a suppressive to promoting role of the HP1 family in cancers. For example, HP1g has been shown to be positive in all cancer tissues but is not positive in the matching normal epithelium (Takanashi et al. 2009 ). Consistently, suppression of HP1g expression restrains the proliferation of various cancer cell types, but not that of normal cells, suggesting that HP1g is a promising therapeutic target (Takanashi et al. 2009) . Similarly, HP1a expression is upregulated in various tumor tissues in contrast to the corresponding normal tissues without detectable HP1a expression, as well as in highly malignant breast cancers with poor patient survival (De Koning et al. 2009 ). In addition, HP1-related methyltransferase G9a has been reported to promote lung cancer invasion and metastasis (Chen et al. 2010) . In addition, we have recently shown that HP1b is upregulated with an increased Gleason score in prostate cancer (Shiota et al. 2010a) . Takanashi et al. (2009) reported that re-expression of HP1g by overexpression maintains human pre-adipocytes in an undifferentiated state even with HP1g suppression by a differentiation inducer, suggesting a role of HP1g re-expression in maintaining the undifferentiated state of cells. Similarly, the HP1 family has been shown to be downregulated in differentiated blood lymphocytes compared with that in their undifferentiated precursors (Gilbert et al. 2003 , Baxter et al. 2004 , Ritou et al. 2007 . Taken together, these results indicate that loss of HP1g expression is essential for differentiation, suggesting a function as a safety mechanism for the transition to cellular differentiation. Consistently, our results showed that HP1g knockdown suppressed prostate cancer cell growth, whereas overexpression of HP1g showed no significant effect on cell proliferation. This result indicates that HP1g overexpression is unnecessary for cell proliferation at least in our experimental setting, although it is necessary to maintain cell cycling.
By contrast, HP1a overexpression promoted prostate cancer cell proliferation, whereas HP1a silencing exerted no apparent suppressive effect on cell growth, which is consistent with a previous report showing that HP1a knockdown does not affect cell proliferation (Norwood et al. 2006) or cell cycle distribution (De Koning et al. 2009 ). Furthermore, the proliferation-promoting role of HP1a is consistent with previous findings indicating that oncogenic E2F (Weinmann et al. 2002 , Oberley et al. 2003 and myc (Li et al. 2003 , Kim et al. 2008 ) transcription factors positively regulate HP1a expression. These results appear to indicate a role of HP1a in cell proliferation as a growth factor, which can be substituted by other factors.
In addition to the tumor-promoting role of HP1 proteins, we revealed a role of HP1 isoforms in AR singling. We previously reported the role of HP1b as an AR coactivator in prostate cancer. In addition, we revealed the role of HP1a and HP1g in AR expression: HP1a overexpression induced AR expression while HP1g knockdown reduced AR expression, by overexpression and knockdown methods respectively. Although these findings were not recapitulated by reversing the expression of HP1a and HP1g, they were correlated with cell proliferation, which was consistent with the role of the AR in cell proliferation of prostate cancer. As HP1b knockdown did not affect cell proliferation in AR-negative PC-3 cells (Shiota et al. 2010a) , AR signaling may mediate the effect on cell proliferation by HP1, especially HP1b.
Overexpression of CD-or CSD-deleted HP1g partially exerted a similar effect as that of full-length HP1g, indicating that both the CD and CSD of HP1g can retain partial activity of full-length HP1g (Takanashi et al. 2009 ). Similarly, our study showed that HP1a DC exerted similar effects on AR signaling and prostate cancer cell proliferation as those of full-length HP1a, suggesting a supporting or compensating role of the CD of HP1a for full-length HP1a.
Intriguingly, HP1 isoforms are thought to be implicated in the DNA damage response induced by various toxins including oxidative stress (Dinant & Luijsterburg 2009) . HP1 is recruited to damaged regions of DNA and facilitates the DNA repair pathway activated by oxidative lesions (Zarebski et al. 2009 ). These findings are interesting because it has been shown that oxidative stress is induced by androgen deprivation (Shiota et al. 2010b) and is increased in CRPC (Shigemura et al. 2007) , which is consistent with upregulation of HP1a and HP1b in CRPC cells and their promoting role in AR signaling and cell proliferation in prostate cancer. These results indicate that HP1 isoforms participate in cross talk between oxidative stress and AR signaling in prostate cancer. Moreover, HP1 isoforms may augment therapeutic effects by genotoxic anticancer therapy that exerts oxidative stress, which is supported by the finding that a higher sensitivity to ionizing radiation is also observed in HP1a-or HP1b-overexpressing cells (Sharma et al. 2003) .
In conclusion, HP1 isoforms distinctly promote AR signaling and prostate cancer growth, which may
